MedPath

Fruquintinib

Generic Name
Fruquintinib
Brand Names
Fruzaqla
Drug Type
Small Molecule
Chemical Formula
C21H19N3O5
CAS Number
1194506-26-7
Unique Ingredient Identifier
49DXG3M5ZW
Background

Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication

本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Clinical Trials
Related News

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Colon Cancer
Metastatic Colon Cancer
Interventions
Drug: FOLFIRI regimen & bevacizumab
First Posted Date
2023-05-08
Last Posted Date
2025-05-11
Lead Sponsor
Sapience Therapeutics
Target Recruit Count
115
Registration Number
NCT05848739
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Westchester Medical Center, Valhalla, New York, United States

🇺🇸

Fred Hutch Cancer Center, Seattle, Washington, United States

and more 8 locations

Fruquintinib and SeRplulimab: Opening New Frontiers in Treating Non-clear Cell Renal Cell Carcinoma

Phase 2
Recruiting
Conditions
Non-clear Renal Cell Carcinoma
Interventions
First Posted Date
2023-04-26
Last Posted Date
2024-12-19
Lead Sponsor
RenJi Hospital
Target Recruit Count
39
Registration Number
NCT05831891
Locations
🇨🇳

Renji Hospital, Shanghai, Shanghai, China

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Phase 2
Active, not recruiting
Conditions
Stomach Neoplasms
Interventions
First Posted Date
2023-04-03
Last Posted Date
2023-08-30
Lead Sponsor
RenJi Hospital
Target Recruit Count
30
Registration Number
NCT05795296
Locations
🇨🇳

Renji Hospital, Shanghai, China

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Phase 2
Not yet recruiting
Conditions
Colorectal Cancer
Microsatellite Stable Colorectal Carcinoma
Interventions
First Posted Date
2023-03-16
Last Posted Date
2023-03-16
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05771181
Locations
🇨🇳

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

Phase 2
Recruiting
Conditions
Rectal Cancer
Interventions
Radiation: Short-course radiotherapy
Procedure: TME
First Posted Date
2023-03-10
Last Posted Date
2023-03-10
Lead Sponsor
West China Hospital
Target Recruit Count
44
Registration Number
NCT05763927
Locations
🇨🇳

West China Hospital, Sichuan University, Chengdu, Sichuan, China

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Phase 2
Recruiting
Conditions
Metastatic Colorectal Cancer
Interventions
First Posted Date
2022-12-21
Last Posted Date
2023-01-06
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
40
Registration Number
NCT05659290
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

Phase 2
Not yet recruiting
Conditions
Gastric Cancer
Interventions
First Posted Date
2022-12-09
Last Posted Date
2022-12-09
Lead Sponsor
Fujian Medical University
Target Recruit Count
47
Registration Number
NCT05643677

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Phase 2
Recruiting
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
First Posted Date
2022-12-05
Last Posted Date
2022-12-05
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
48
Registration Number
NCT05636150
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Phase 2
Not yet recruiting
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: FOLFIRI
Drug: mFOLFOX6
First Posted Date
2022-12-02
Last Posted Date
2022-12-02
Lead Sponsor
Fudan University
Target Recruit Count
68
Registration Number
NCT05634590
Locations
🇨🇳

Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Phase 2
Not yet recruiting
Conditions
Stomach Neoplasms
Interventions
First Posted Date
2022-11-23
Last Posted Date
2022-11-23
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
29
Registration Number
NCT05625737
Locations
🇨🇳

Wuhan Union Hospital, China, Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy